
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx Inc has demonstrated a positive financial trajectory, reporting an 18% year-over-year revenue increase to $483 million, with a robust peak sales guidance that forecasts over $1 billion by 2029. The company's strategic initiatives, such as the ongoing Phase 3 trial for IBSRELA and enhanced prescription metrics for XPHOZAH, including a notable 41% growth in its ex-Medicare segment, indicate strong market demand and potential for substantial future growth. Ardelyx's investments in patient assistance programs and sales infrastructure are expected to further boost prescription volumes and overall revenue performance.
Bears say
Ardelyx Inc. faces a challenging outlook as management anticipates a typical seasonal decline in Ibsrela revenue, projecting an 18% quarter-over-quarter drop for 1Q26 despite an overall estimate of $422M for FY26. The company's aggressive guidance of over $1B in peak Ibsrela net sales appears unrealistic, compounded by potential adverse effects from changing reimbursement pricing structures and the risk of key product labels lacking essential features. Additionally, Ardelyx reported a net loss of $0.4M for 4Q25, highlighting concerns over market penetration and revenue generation, particularly as adherence issues with phosphate binder therapy persist, affecting patient treatment outcomes.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares